Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.


Dr. Mayer on Toxicities Associated With Therapies for ER+ Breast Cancer

October 6th 2015

Ingrid A. Mayer, MD, associate professor of medicine, co-leader and clinical director, Breast Cancer Research Program, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses toxicities that are associated with therapies for ER-positive metastatic breast cancer.

Dr. Boughey on Locoregional Trials for Breast Cancer

September 27th 2015

Judy C. Boughey, MD, chair, Division of Surgery Research, Mayo Clinic, discusses locoregional clinical trials for breast cancer.

T.S. Wiley on Bio-identical Hormone Replacement Therapy for Patients With Breast Cancer

September 27th 2015

T.S. Wiley, CEO, Wiley Protocol Systems, discusses a study that examined the efficacy of biomemetic bio-identical hormone replacement therapy for patients with metastatic breast cancer.

Dr. Kapoor on Multigene Panel Testing for Patients at Risk for Breast Cancer

September 26th 2015

Nimmi S. Kapoor, MD, surgical oncologist, Breastlink Laguna Hills and Breastlink Orange, discusses the benefits and safety of multigene panel testing in patients who are at risk for hereditary breast cancer.

Breast Cancer Pioneer Examines Novel Therapies for Metastatic Breast Cancer

September 3rd 2015

Dennis Slamon, MD, PhD, discusses the inhibition of CDK 4/6 and PD-1, which represent two of the most exciting developments in the field of metastatic breast cancer.

Fertility Concerns Impact Breast Cancer Treatment Decisions

August 28th 2015

Young women with breast cancer may decline, discontinue tamoxifen because of fertility concerns.

Dr. O'Shaughnessy Discusses New Developments in Molecular Profiling in Breast Cancer

August 27th 2015

Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses new developments in molecular profiling in patients with metastatic breast cancer.

Medivation Acquires BioMarin's PARP Inhibitor Talazoparib

August 25th 2015

Medivation has announced that it will purchase the PARP inhibitor talazoparib (BMN-673) from BioMarin Pharmaceutical for $410 million, with additional milestone and royalty payments of up to $160 million.

Dr. O'Shaughnessy on Using Phosphoprotein Assays to Personalize Treatment for Breast Cancer

August 21st 2015

Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses how the results of phosphoprotein assays can impact treatment decisions for select patients with advanced breast cancer.

Molecular Imaging May Help Tailor Breast Cancer Therapies

August 13th 2015

Although many drugs are under study for patients with metastatic breast cancer, there is a pressing need to establish methods of predicting response and improving drug delivery, and researchers are looking toward molecular imaging techniques to help reach those goals.

Dr. O'Shaughnessy on Adding Phosphoprotein Testing to Genomic Testing for Breast Cancer

August 13th 2015

Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses insights from adding phosphoprotein testing to genomic testing for patients with breast cancer.

Dr. Shannon Puhalla on PALOMA-3 Updates

August 13th 2015

Shannon Puhalla, MD Assistant Professor of Medicine, Division of Hematology, University of Pittsburgh, discusses recent updates of the PALOMA-3 trial.

Oncologists Urged to Help Obese Breast Cancer Patients Manage Weight

August 12th 2015

There is clear evidence that obesity at the time of diagnosis of operable breast cancer is associated with an increased risk of distant recurrence, specifically for HR–positive, HER2-negative disease, and oncologists should consider helping patients better manage their weight as part of their treatment plans.

O'Shaughnessy Details Strategies to Strengthen ER Blockade in MBC

August 11th 2015

Combining estrogen receptor blockade with targeted cell-cycle inhibitors increases therapeutic options for postmenopausal women with ER-positive, HER2-negative metastatic breast cancer, contributing to an evolving paradigm that is moving new regimens to the forefront of the treatment timeline.

Dr. Mamounas on Patient Selection for Endocrine Therapy

August 7th 2015

Eleftherios P. Mamounas, MD, surgical oncologist, UF Health Cancer Center - Orlando Health, discusses which patients with breast cancer are most likely to benefit from endocrine therapy.

Dr. O'Shaughnessy on Phosphoprotein Assays for Treatment Decision-Making for Breast Cancer

August 5th 2015

Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses what recent research has shown regarding phosphoprotein assays in treatment decision-making for patients with breast cancer.

Dr. Jahanzeb on Overcoming HER2 Resistance in Breast Cancer

August 4th 2015

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology Oncology, University of Miami's Miller School of Medicine, discusses potential mechanisms for overcoming HER2 resistance in breast cancer.

Dr. Elias on Androgen Receptor Inhibitors in HER2-Positive Breast Cancer

August 4th 2015

Anthony D. Elias, MD, professor, Division of Medical Oncology, University of Colorado School of Medicine, discusses using androgen receptor inhibitors as a potential treatment of patients with HER2-positive breast cancer.

Dr. Chagpar on Sequencing Therapies for HER2-Positive Breast Cancer

August 3rd 2015

Anees B. Chagpar, MD, MA, MPH, MBA, FRCS(C), FACS, associate professor of surgery (oncology), director, The Breast Center at Smilow Cancer Hospital at Yale-New Haven, assistant director, Global Oncology, Yale Comprehensive Cancer Center, discusses sequencing therapies for patients with HER2-positive breast cancer.

Neoadjuvant Pertuzumab Regimen Approved in Europe for HER2-Positive Early Breast Cancer

July 31st 2015

The European Commission has approved the combination of pertuzumab, trastuzumab, and chemotherapy as a neoadjuvant therapy for adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer who are at high risk of recurrence.

NEXT PAGE
PREVIOUS PAGE